AIM ImmunoTech Secures Broad US Patent for Rintatolimod (Ampligen®) Used in Combination with Keytruda, Expanding Oncology IP Protection for Ampligen Through 2039
“The issuance of this patent marks another significant step in building a broad and durable intellectual property patent estate around Ampligen’s potential role in cancer immunotherapy,” said Thomas Equels, Chief Executive Officer of AIM ImmunoTech. “This patent protects Ampligen’s use in combination therapy with the leading PD-1 checkpoint therapy across a broad range of cancers and specifically encompasses pancreatic cancer, the central focus of our late-stage oncology strategy. Together with our existing U.S. and international patents covering Ampligen with PD-1 and PD-L1 checkpoint blockade, we believe this growing patent estate strengthens both the scientific and strategic foundation supporting Ampligen’s long-term oncology opportunity.”
Share:
More News
“Fast Track designation in lung cancer represents an important milestone for TRE-515 and further validates our strategy of combining dCK inhibition with targeted cancer therapies,” said Dr. Ken Schultz, Trethera Chairman and CEO. “KRAS G12C inhibitors have transformed the NSCLC treatment landscape, but resistance and incomplete responses remain major challenges.
“AvenCell has built a differentiated cell therapy platform that brings together CRISPR-engineered allogeneic CAR-T technology with a unique switchable CAR approach designed to provide greater control over CAR-T activity,” said Todd Davis, CEO of Ligand. “We believe the combination of these technologies, together with the encouraging clinical data generated to
“Advanced gastric cancer is characterized by substantial biological and clinical heterogeneity. Previous studies have shown that the magnitude of benefit from PD-1 inhibitor therapy is closely associated with PD-L1 expression, and that there remains room to further improve outcomes, particularly in patients with low PD-L1 expression. How to broaden the
“The evERA results represent an important step forward for people with ER-positive advanced breast cancer and underscore the potential for giredestrant to help address the challenge of disease progression in this setting,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. “Together with the